Brent Burger

Psychometric Validation of the QLQ-NMIBC24 in Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Veronica Lee, Nikky Ugwuoke, Michael J. Louie, Brent Burger et autres

Purpose: This study aimed to evaluate the psychometric properties of the EORTC QLQ-NMIBC24 and to propose distribution-based minimal clinically important difference (MCID) thresholds in patients with low-grade, intermediate-risk NMIBC (LG-IR-NMIBC). Patients and Methods: Patients with LG-IR-NMIBC from two phase 3 trials (ATLAS, …

us (code pays fourni par la source)

Assessing responses to UGN-102 across EORTC recurrence score groups in patients with recurrent low-grade intermediate-risk NMIBC (ENVISION trial).

Sandip M. Prasad, William Huang, Michael J. Louie, Nikky Ugwuoke et autres

4601 Background: The ENVISION phase 3 study (NCT05243550) treated patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) with UGN-102, a reverse thermal hydrogel administered intravesically containing 75 mg mitomycin. Complete response (CR) rate at 3 months was 79.6% (95% confidence interval …

us (code pays fourni par la source)

UTOPIA: A phase 3 trial of UGN-103, an intravesical mitomycin reverse thermal hydrogel, in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

Abhishek Srivastava, Egils Vjaters, Hristos Z. Kaimakliotis, Sandip M. Prasad et autres

4604 Background: Management of recurrent low-grade (LG), intermediate-risk (IR) non-muscle invasive bladder cancer (NMIBC) remains challenging due to frequent recurrence following standard surgical management with transurethral resection of bladder tumor (TURBT). UGN-102 is an intravesical mitomycin reverse thermal hydrogel, approved by the …

us, lv (code pays fourni par la source)

Reply by Authors

Sandip M. Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, Pencho Genov et autres

us, bg (code pays fourni par la source)

PD25-03 TREATMENT WITH UGN-102 IN PATIENTS WITH RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER: 24-MONTH DURATION OF RESPONSE DATA FROM THE PHASE 3 ENVISION TRIAL

Sandip M. Prasad, Nikola V. Mihaylov, Pencho Genov, Vasyl Terzi et autres

IP02-23 DURATION OF RESPONSE TO UGN-102 BY AGE AT BASELINE ACROSS 3 CLINICAL TRIALS IN PATIENTS WITH LOW-GRADE INTERMEDIATE-RISK BLADDER CANCER

Ashish M. Kamat, William C. Huang, Neal D. Shore, Michael J. Louie et autres

UGN-102 for Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial

Sandip M. Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, Pencho P. Genov et autres

PURPOSE: We report the duration of response to UGN-102 treatment in patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC) 24 months after achieving complete response (CR). MATERIALS AND METHODS: ENVISION is an ongoing, multinational, single-arm, phase 3 study in patients with …

us, bg (code pays fourni par la source)

Patient-Reported Outcomes Following UGN-102 Treatment in Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: An Analysis of 3 Clinical Trials.

Max Kates, Victoria Tsurutis, Anagha Nadkarni, L Veronica Lee et autres

UGN-102 is a reverse thermal hydrogel formulation of mitomycin indicated for nonsurgical intravesical treatment of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC). This analysis evaluates patient-reported outcomes (PROs) for quality of life (QoL), functioning, and symptom burden across 3 late-phase clinical trials …

us (code pays fourni par la source)

Response to primary chemoablation with UGN-102 in different EOTRC risk groups.

William J. Huang, Sandip Prasad, Michael J. Louie, Nikky Ugwuoke et autres

733 Background: The ENVISION phase 3 study (NCT05243550) treated patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) with UGN-102, a reverse thermal hydrogel administered intravesically containing 75 mg mitomycin. Complete response (CR) rate at 3 months was 79.6% (95% confidence interval …

us (code pays fourni par la source)

Psychometric Validation of the QLQ-NMIBC24 in Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Charles Peyton, Rahul Dhanda, Tom Burke, Victoria Tsurutis et autres

Purpose: This study aimed to evaluate the psychometric properties of the EORTC QLQ-NMIBC24 and to propose distribution-based minimal clinically important difference (MCID) thresholds in patients with low-grade, intermediate-risk NMIBC (LG-IR-NMIBC). Patients and Methods: Patients with LG-IR-NMIBC from two phase 3 trials (ATLAS, …

us, gb (code pays fourni par la source)

Patient-Reported Outcomes Following UGN-102 Treatment in Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: An Analysis of 3 Clinical Trials

Cheri L. Peyton, Max R. Kates, Anagha Nadkarni, Rahul Dhanda et autres

INTRODUCTION: UGN-102 is a reverse thermal hydrogel formulation of mitomycin indicated for nonsurgical intravesical treatment of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC). This analysis evaluates patient-reported outcomes (PROs) for quality of life (QoL), functioning, and symptom burden across 3 late-phase clinical …

us, gb (code pays fourni par la source)

Pharmacokinetics of UGN‑102, an investigational mitomycin‑containing reverse thermal gel for the treatment of non-muscle invasive bladder cancer

Sandip M. Prasad, Michael J. Louie, Brent Burger, Victoria Tsurutis et autres

To evaluate the pharmacokinetic properties of UGN-102, a mitomycin-containing reverse thermal gel. Twelve patients with NMIBC received 6 once-weekly intravesical instillations of UGN-102 (BL004: 120 mg mitomycin [ n = 6]; BL005: 75 mg mitomycin [ n = 6]). Plasma samples for …

us (code pays fourni par la source)